Wahl, K;
Rosenberg, W;
Vaske, B;
Manns, MP;
Schulze-Osthoff, K;
Bahr, MJ;
Bantel, H;
(2012)
Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.
PLoS One
, 7
(12)
, Article e51906. 10.1371/journal.pone.0051906.
![[thumbnail of 1384559.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1384559.pdf Download (308kB) |
Abstract
Chronic liver diseases are characterized by inflammatory and fibrotic liver injuries that often result in liver cirrhosis with its associated complications such as portal hypertension and hepatocellular carcinoma. Liver biopsy still represents the reference standard for fibrosis staging, although transient elastography is increasingly used for non-invasive monitoring of fibrosis progression. However, this method is not generally available and is associated with technical limitations emphasizing the need for serological biomarkers staging of liver fibrosis. The enhanced liver fibrosis (ELF) score was shown to accurately predict significant liver fibrosis in different liver diseases, although extracellular matrix components detected by this score may not only mirror the extent of liver fibrosis but also inflammatory processes.
| Type: | Article |
|---|---|
| Title: | Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0051906 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pone.0051906 |
| Language: | English |
| Additional information: | © 2012 Wahl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This study was supported by the Deutsche Forschungsgemeinschaft (SFB Transregio 77, SFB 685, BA 2092/9-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. WR is an inventor of the ELF test and has received support for research studies and speaking events from Siemens Healthcare Diagnostics Inc. The proprietary assays developed for the ELF test by Siemens Healthcare Diagnostics Inc. (Tarrytown, New York, United States of America) were used and analyses were performed on an Immuno-1 auto-analyser (Siemens Healthcare Diagnostics Inc., Tarrytown, New York, United States of America). There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1384559 |
Archive Staff Only
 |
View Item |
